Predict your next investment

Venture Capital
amvpartners.com

See what CB Insights has to offer

Investments

87

Portfolio Exits

11

Funds

2

Service Providers

1

About Accuitive Medical Ventures

Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. We have offices in Palo Alto, CA, Atlanta, GA, Rochester, MN and Fernandina Beach, FL. We are a market driven firm looking for revolutionary, early stage medical device and technology investment opportunities.

Accuitive Medical Ventures Headquarter Location

2750 Premiere Parkway, Suite 200

Duluth, Georgia, 30097,

United States

(678) 812 1101

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Accuitive Medical Ventures News

Myoscience closes $10 million financing

Mar 12, 2018

California-based medical technology innovator, Myoscience, Inc. announced today the first closing of a private financing of $10 million from its current investors led by Valiance Asset Management Limited (“Valiance”) and Accuitive Medical Ventures. Included with this financing is the conversion of promissory notes with principal of approximately $21 million. This financing allows needed funds to continue with the commercial roll-out of its products. Myoscience manufactures the ioveraº system, a non-opioid and non-systemic treatment for blocking pain signals from various peripheral nerves . Cary G. Vance, President and CEO of Myoscience, stated “We are keenly aware that there’s an opioid epidemic in our country and ioveraº has been shown to decrease the use of opioids in the TKA market and generally. We are pleased to have the support from our investors that will enable us to pursue commercial market adoption for ioveraº in advance of TKA procedures and in connection with osteoarthritis to reduce pain and reduce opioid use.” Proceeds from this financing will be used to expand the Company’s sales force, expand the Company’s product offering and clinical program, increase product manufacturing and for general corporate purposes to help meet the growing demand for the ioveraº technology within the perioperative and chronic pain market segments of the knee. Jan Pensaert, Board member and CEO of lead investor Valiance stated "We are excited to see expanding market acceptance of Myoscience products in the medical community to better manage pain. Beyond our initial market focus on surgical or chronic knee pain, this technology has broad application for many parts of the body which is consistent with Myoscience’s clinical studies roadmap to validate new treatment indications.” Myoscience’s iovera° system is a small, hand-held device that uses disposable tips to deliver focused cold to targeted nerves. It has been well proven to be safe and effective as a stand-alone, non-opioid modality for managing chronic, perioperative and acute pain. The iovera° treatment provides immediate, long-lasting pain relief by blocking the nerve’s ability to transmit pain signals without affecting the structure of the targeted nerve. The iovera° system is approved by US FDA for the blocking of pain and for relieving pain and symptoms associated with osteoarthritis of the knee for up to 90 days. For additional information, please visit http://www.iovera.com or email us directly at contact@myoscience.com. ABOUT MYOSCIENCE Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by the Focused Cold Therapy® delivery system, a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com . ABOUT CHRONIC AND PERIOPERATIVE KNEE PAIN More than 10 million people in the US suffer from moderate to severe osteoarthritis in the knee joint. These patients typically suffer from chronic pain until the disease progresses to a severe condition when they may receive an implant using the total knee arthroplasty (TKA) procedure. Less than one in ten patients (approximately 900,000 annually) who suffer from osteoarthritis in the knee receive TKA. The iovera technology has been proven to successfully treat both chronic and perioperative pain of the knee through two very robust, level-1 clinical studies 1,2. 1. Radnovich, R. et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthritis and Cartilage (2017) p1-10. 2. Dasa, V. et al. Percutaneous freezing of sensory nerves prior to total knee arthroplasty. The Knee (2016) p523-528. © 2018 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0485 REV A Forward-Looking Statements All statements, other than statements of historical fact, that address activities, events or developments that Myoscience intends, expects, projects, believes, hopes or anticipates will or may occur in the future are forward-looking statements. These statements are based upon certain assumptions and assessments made by Myoscience management and are subject to a number of material risks and uncertainties. Actual results may differ materially, and reported results should not be considered as an indication of future performance. The forward-looking statements represent Myoscience’s assumptions and assessments as of the date of this press release, and Myoscience undertakes no obligation to correct, update or revise the forward-looking statements in this press release for any reason. For the original version on PRWeb visit: http://www.prweb.com/releases/2018/03/prweb15303688.htm

Accuitive Medical Ventures Investments

87 Investments

Accuitive Medical Ventures has made 87 investments. Their latest investment was in ActivOrtho as part of their Unattributed VC - IV on September 9, 2020.

CBI Logo

Accuitive Medical Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/18/2020

Unattributed VC - IV

ActivOrtho

$0.22M

No

1

7/20/2020

Unattributed VC - II

CardioFocus

$12.02M

No

1

12/4/2019

Unattributed VC - III

ActivOrtho

$1.12M

No

1

5/30/2019

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2019

Series I

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/18/2020

7/20/2020

12/4/2019

5/30/2019

5/29/2019

Round

Unattributed VC - IV

Unattributed VC - II

Unattributed VC - III

Unattributed VC

Series I

Company

ActivOrtho

CardioFocus

ActivOrtho

Subscribe to see more

Subscribe to see more

Amount

$0.22M

$12.02M

$1.12M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Accuitive Medical Ventures Portfolio Exits

11 Portfolio Exits

Accuitive Medical Ventures has 11 portfolio exits. Their latest portfolio exit was Respicardia on April 12, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/12/2021

Acquired

$99M

7

3/5/2019

Acquired

$99M

3

6/28/2018

IPO

$99M

Public

3

2/17/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/4/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/12/2021

3/5/2019

6/28/2018

2/17/2017

9/4/2015

Exit

Acquired

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

7

3

3

10

10

Accuitive Medical Ventures Fund History

2 Fund Histories

Accuitive Medical Ventures has 2 funds, including AMV Partners II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/10/2007

AMV Partners II LP

Early-Stage Venture Capital

Closed

$175M

1

12/31/2004

AMV Partners I LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/10/2007

12/31/2004

Fund

AMV Partners II LP

AMV Partners I LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$175M

$99M

Sources

1

10

Accuitive Medical Ventures Service Providers

1 Service Provider

Accuitive Medical Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Accuitive Medical Ventures Team

10 Team Members

Accuitive Medical Ventures has 10 team members, including current Chief Financial Officer, Gordon T. Wyatt.

Name

Work History

Title

Status

Michael Partsch

Founder

Current

Thomas D. Weldon

Founder

Current

Gordon T. Wyatt

Chief Financial Officer

Current

Gerard Van Hamel

Managing Director

Current

Charles E. Larsen

Managing Director

Current

Name

Michael Partsch

Thomas D. Weldon

Gordon T. Wyatt

Gerard Van Hamel

Charles E. Larsen

Work History

Title

Founder

Founder

Chief Financial Officer

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.